Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects

Current Pharmaceutical Biotechnology

Volumn 15, Issue 7, 2014, Pages 609-619

  Araújo, Francisca ^a,b,c   Shrestha, Neha ^c   Granja, Pedro L ^a,b   Hirvonen, Jouni ^c   Santos, Hélder A ^c   Sarmento, Bruno ^a,d  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide; Incretins; lipids; Mesoporous materials; Microparticles; Nanoparticles; Oral drug delivery; Polymers

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; TASPOGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; MICROSPHERE; NANOPARTICLE;

ANTIDIABETIC ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; GASTROINTESTINAL TRACT FUNCTION; GLUCONEOGENESIS; GLUCOSE REGULATION SYSTEM; HORMONAL REGULATION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MICROSPHERES; NANOPARTICLES;

EID: 84925868886     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140915150312     Document Type: Article

References (99)

1. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabet. Res. Clin. Pract., 2010, 87(1), 4-14.
2. Tahrani, A.A.; Piya, M.K.; Kennedy, A.; Barnett, A.H. Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacol. Ther., 2010, 125(2), 328-361.
3. Namba, M.; Katsuno, T.; Kusunoki, Y.; Matsuo, T.; Miuchi, M.; Miyagawa, J. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin. Exp. Nephrol., 2013, 17(1), 10-15.
4. Zhang, P.; Zhang, X.; Brown, J.; Vistisen, D.; Sicree, R.; Shaw, J.; Nichols, G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabet. Res. Clin. Pract., 2010, 87(3), 293-301.
5. Nicholson, G.; Hall, G.M. Diabetes mellitus: new drugs for a new epidemic. Br. J. Anaesth., 2011, 107(1), 65-73.
6. Arulmozhi, D.K.; Portha, B. GLP-1 based therapy for type 2 diabetes. Eur. J. Pharm. Sci., 2006, 28(1-2), 96-108.
7. Campbell, J.E.; Drucker, D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab., 2013, 17(6), 819-837.
8. Drucker, D.J. The biology of incretin hormones. Cell Metabolism, 2006, 3(3), 153-165.
9. Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368(9548), 1696-1705
10. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132(6), 2131-2157.
11. Khan, M.A.; Deaton, C.; Rutter, M.K.; Neyses, L.; Mamas, M.A. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev., 2013, 18(2), 141-148.
12. Vilsboll, T.; Krarup, T.; Madsbad, S.; Holst, J.J. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet. Med., 2001, 18(2), 144-149.
13. Bavec, A. (Poly)peptide-based therapy for diabetes mellitus: Insulins versus incretins. Life Sci, 2014, 99(1-2), 7-13.
14. Nauck, M.A.; Vardarli, I.; Deacon, C.F.; Holst, J.J.; Meier, J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia, 2011, 54(1), 10-18.
15. Nauck, M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med., 2011, 124(1), 3-18.
16. Portha, B.; Tourrel-Cuzin, C.; Movassat, J. Activation of the GLP-1 receptor signalling pathway: A relevant strategy to repair a deficient beta-cell mass. Exp. Diabet. Res., 2011, 2011(376509).
17. Holst, J.J.; Christensen, M.; Lund, A.; de Heer, J.; Svendsen, B.; Kielgast, U.; Knop, F.K. Regulation of glucagon secretion by incretins. Diabetes Obes. Metab., 2011, 13(1), 89-94.
18. Perfetti, R.; Merkel, P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur. J. Endocrinol., 2000, 143(6), 717-725.
19. Gutzwiller, J.P.; Drewe, J.; Goke, B.; Schmidt, H.; Rohrer, B.; Lareida, J.; Beglinger, C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol., 1999, 276(5), R1541-1544.
20. Neumiller, J.J. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin. Ther., 2011, 33(5), 528-576.
21. Davidson, M.H., Cardiovascular effects of glucagonlike peptide-1 agonists. Am. J. Cardiol., 2011, 108(3), 33B-41B.
22. Marre, M.; Penfornis, A. GLP-1 receptor agonists today. Diabet. Res. Clin. Pract., 2011, 93(3), 317-327.
23. Russell, S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm., 2013, 35(2), 159-172.
24. Araujo, F.; Fonte, P.; Santos, H.A.; Sarmento, B. Oral delivery of glucagon-like peptide-1 and analogs: Alternatives for diabetes control? J. Diabet. Sci. Technol., 2012, 6(6), 1486-1497.
25. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev., 2007, 87(4), 1409-1439.
26. Juillerat-Jeanneret, L. Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else? J. Medicin. Chem., 2014, 57(6), 2197-2212.
27. Gerich, J. Pathogenesis and management of postprandial hyperglycemia: Role of incretin-based therapies. Int. J. Gen. Med., 2013, 6, 877-895.
28. Unger, J.R.; Parkin, C.G. Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. Diabet. Ther., 2011, 2(1), 29-39.
29. Li, Y.; Zheng, X.; Tang, L.; Xu, W.; Gong, M. GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. Peptides, 2011, 32(6), 1303-1312.
30. Deacon, C.F. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc. Health Risk Manag., 2009, 5(1), 199-211.
31. Steinert, R.E.; Poller, B.; Castelli, M.C.; Friedman, K.; Huber, A.R.; Drewe, J.; Beglinger, C. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin. Pharmacol. Ther., 2009, 86(6), 644-650.
32. Beglinger, C.; Poller, B.; Arbit, E.; Ganzoni, C.; Gass, S.; Gomez-Orellana, I.; Drewe, J. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin. Pharmacol. Ther., 2008, 84(4), 468-474.
33. Shahbazi, M.A.; Santos, H.A. Improving oral absorption via drugloaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr. Drug Metab., 2013, 14(1), 28-56.
34. Rekha, M.R.; Sharma, C.P. Oral delivery of therapeutic protein/ peptide for diabetes--future perspectives. Int. J. Pharm., 2013, 440(1), 48-62.
35. Antunes, F.; Andrade, F.; Ferreira, D.; Nielsen, H.M.; Sarmento, B. Models to predict intestinal absorption of therapeutic peptides and proteins. Curr. Drug Metab., 2013, 14(1), 4-20.
36. Chen, M.C.; Sonaje, K.; Chen, K.J.; Sung, H.W. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials, 2011, 32(36), 9826-9838.
37. Ensign, L.M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev., 2012, 64(6), 557-570.
38. das Neves, J.; Bahia, M.F.; Amiji, M.M.; Sarmento, B. Mucoadhesive nanomedicines: Characterization and modulation of mucoadhesion at the nanoscale. Expert Opin. Drug Deliv., 2011, 8(8), 1085-1104.
39. Gao, W.; Chan, J.M.; Farokhzad, O.C. pH-Responsive nanoparticles for drug delivery. Mol. Pharm., 2010, 7(6), 1913-1920.
40. Blanchette, J.; Kavimandan, N.; Peppas, N.A. Principles of transmucosal delivery of therapeutic agents. Biomed. Pharmacother., 2004, 58(3), 142-151.
41. Attivi, D.; Wehrle, P.; Ubrich, N.; Damge, C.; Hoffman, M.; Maincent, P. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev. Ind. Pharm., 2005, 31(2), 179-189.
42. Damge, C.; Maincent, P.; Ubrich, N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control Release, 2007, 117(2), 163-170.
43. Huotari, A.; Xu, W.; Monkare, J.; Kovalainen, M.; Herzig, K.H.; Lehto, V.P.; Jarvinen, K. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity. Int. J. Pharm., 2013, 454(1), 67-73.
44. Kilpelainen, M.; Monkare, J.; Vlasova, M.A.; Riikonen, J.; Lehto, V.P.; Salonen, J.; Jarvinen, K.; Herzig, K.H. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur. J. Pharm. Biopharm., 2011, 77(1), 20-25.
45. Li, X.; Guo, S.; Zhu, C.; Zhu, Q.; Gan, Y.; Rantanen, J.; Rahbek, U.L.; Hovgaard, L.; Yang, M. Intestinal mucosa permeability fol lowing oral insulin delivery using core shell corona nanolipoparticles. Biomaterials, 2013, 34(37), 9678-9687.
46. Zhang, Z.H.; Zhang, Y.L.; Zhou, J.P.; Lv, H.X. Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomed., 2012, 7, 3333-3339.
47. Zhang, Z.; Lv, H.; Zhou, J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie, 2009, 64(9), 574-578.
48. Zhang, N.; Ping, Q.; Huang, G.; Han, X.; Cheng, Y.; Xu, W. Transport characteristics of wheat germ agglutinin-modified insulin-liposomes and solid lipid nanoparticles in a perfused rat intestinal model. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2959-2966.
49. Desai, P.P.; Date, A.A.; Patravale, V.B. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov. Today Technol., 2012, 9(2), e71-e174.
50. Hunter, A.C.; Elsom, J.; Wibroe, P.P.; Moghimi, S.M. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Maturitas, 2012, 73(1), 5-18.
51. Woitiski, C.B.; Sarmento, B.; Carvalho, R.A.; Neufeld, R.J.; Veiga, F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm., 2011, 412(1-2), 123-131.
52. Sahana, D.K.; Mittal, G.; Bhardwaj, V.; Kumar, M.N. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J. Pharm. Sci., 2008, 97(4), 1530-1542.
53. Martin-Banderas, L.; Duran-Lobato, M.; Munoz-Rubio, I.; Alvarez-Fuentes, J.; Fernandez-Arevalo, M.; Holgado, M.A. Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini. Rev. Med. Chem., 2013, 13(1), 58-69.
54. Joseph, J.W.; Kalitsky, J.; St-Pierre, S.; Brubaker, P.L. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia, 2000, 43(10), 1319-1328.
55. Nguyen, H.N.; Wey, S.P.; Juang, J.H.; Sonaje, K.; Ho, Y.C.; Chuang, E.Y.; Hsu, C.W.; Yen, T.C.; Lin, K.J.; Sung, H.W. The glucose-lowering potential of exendin-4 orally delivered via a pHsensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials, 2011, 32(10), 2673-2682.
56. Chuang, E.Y.; Nguyen, G.T.; Su, F.Y.; Lin, K.J.; Chen, C.T.; Mi, F.L.; Yen, T.C.; Juang, J.H.; Sung, H.W. Combination therapy via oral co-administration of insulin-and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials, 2013, 34(32), 7994-8001.
57. Vallet-Regi, M.; Rámila, A.; del Real, R.P.; Pérez-Pariente, J. A New Property of MCM-41: Drug delivery system. Chem. Materials, 2000, 13(2), 308-311.
58. Wang, S. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mats., 2009, 117(1-2), 1-9.
59. Salonen, J.; Kaukonen, A.M.; Hirvonen, J.; Lehto, V.P. Mesoporous silicon in drug delivery applications. J. Pharm. Sci., 2008, 97(2), 632-653.
60. Santos, H.A.; Bimbo, L.M.; Lehto, V.P.; Airaksinen, A.J.; Salonen, J.; Hirvonen, J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr. Drug Discov. Technol., 2011, 8(3), 228-249.
61. Salonen, J.; Lehto, V.-P. Fabrication and chemical surface modification of mesoporous silicon for biomedical applications. Chem. Eng. J., 2008, 137(1), 162-172.
62. Schwartz, M.P.; Cunin, F.; Cheung, R.W.; Sailor, M.J. Chemical modification of silicon surfaces for biological applications. Phys. Status Solidi. A, 2005, 202(8), 1380-1384.
63. Kovalainen, M.; Monkare, J.; Kaasalainen, M.; Riikonen, J.; Lehto, V.P.; Salonen, J.; Herzig, K.H.; Jarvinen, K. Development of porous silicon nanocarriers for parenteral peptide delivery. Mol. Pharm., 2013, 10(1), 353-359.
64. Kinnari, P.; Makila, E.; Heikkila, T.; Salonen, J.; Hirvonen, J.; Santos, H.A. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm., 2011, 414(1-2), 148-156.
65. Salonen, J.; Laitinen, L.; Kaukonen, A.M.; Tuura, J.; Bjorkqvist, M.; Heikkila, T.; Vaha-Heikkila, K.; Hirvonen, J.; Lehto, V.P. Mesoporous silicon microparticles for oral drug delivery: Loading and release of five model drugs. J. Control Release, 2005, 108(2-3), 362-374.
66. Kilpelainen, M.; Riikonen, J.; Vlasova, M.A.; Huotari, A.; Lehto, V.P.; Salonen, J.; Herzig, K.H.; Jarvinen, K. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J. Control Release, 2009, 137(2), 166-170.
67. Kovalainen, M.; Monkare, J.; Makila, E.; Salonen, J.; Lehto, V.P.; Herzig, K.H.; Jarvinen, K. Mesoporous silicon (PSi) for sustained peptide delivery: Effect of psi microparticle surface chemistry on peptide YY3-36 release. Pharm. Res., 2012, 29(3), 837-846.
68. Liu, D.; Bimbo, L.M.; Makila, E.; Villanova, F.; Kaasalainen, M.; Herranz-Blanco, B.; Caramella, C.M.; Lehto, V.P.; Salonen, J.; Herzig, K.H.; Hirvonen, J.; Santos, H.A. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J. Control Release, 2013, 170(2), 268-278.
69. Salonen, J.; Makila, E.; Riikonen, J.; Heikkila, T.; Lehto, V.P. Controlled enlargement of pores by annealing of porous silicon. Phys. Status Solidi. A, 2009, 206(6), 1313-1317.
70. Bimbo, L.M.; Sarparanta, M.; Santos, H.A.; Airaksinen, A.J.; Makila, E.; Laaksonen, T.; Peltonen, L.; Lehto, V.P.; Hirvonen, J.; Salonen, J. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano, 2010, 4(6), 3023-3032.
71. Canham, L.T. Bioactive silicon structure fabrication through nanoetching techniques. Adv. Mater., 1995, 7(12), 1033-1037.
72. Low, S.P.; Voelcker, N.H.; Canham, L.T.; Williams, K.A. The biocompatibility of porous silicon in tissues of the eye. Biomaterials, 2009, 30(15), 2873-2880.
73. Jarvis, K.L.; Barnes, T.J.; Prestidge, C.A. Surface chemistry of porous silicon and implications for drug encapsulation and delivery applications. Adv. Colloid Interf. Sci., 2012, 175, 25-38.
74. Van Speybroeck, M.; Mols, R.; Mellaerts, R.; Thi, T.D.; Martens, J.A.; Van Humbeeck, J.; Annaert, P.; Van den Mooter, G.; Augustijns, P. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur. J. Pharm. Biopharm., 2010, 75(3), 354-365.
75. Ambrogi, V.; Perioli, L.; Marmottini, F.; Giovagnoli, S.; Esposito, M.; Rossi, C. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. Eur. J. Pharm. Sci., 2007, 32(3), 216-222.
76. Chen, J.F.; Ding, H.M.; Wang, J.X.; Shao, L. Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials, 2004, 25(4), 723-727.
77. Kang, J.H.; Oh, D.H.; Oh, Y.-K.; Yong, C.S.; Choi, H.-G. Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). Eur. J. Pharm. Biopharm., 2012, 80(2), 289-297.
78. Tang, B.; Cheng, G.; Gu, J.C.; Xu, C.H. Development of solid selfemulsifying drug delivery systems: Preparation techniques and dosage forms. Drug Discov. Today, 2008, 13(13-14), 606-612.
79. Yan, Y.-D.; Kim, J.A.; Kwak, M.K.; Yoo, B.K.; Yong, C.S.; Choi, H.-G. Enhanced oral bioavailability of curcumin via a solid lipidbased self-emulsifying drug delivery system using a spray-drying technique. Biol. Pharm. Bull., 2011, 34(8), 1179-1186.
80. Yoo, J.H.; Shanmugam, S.; Thapa, P.; Lee, E.S.; Balakrishnan, P.; Baskaran, R.; Yoon, S.K.; Choi, H.G.; Yong, C.S.; Yoo, B.K.; Han, K. Novel self-nanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Arch. Pharm. Res., 2010, 33(3), 417-426.
81. Qu, W.; Li, Y.; Hovgaard, L.; Li, S.; Dai, W.; Wang, J.; Zhang, X.; Zhang, Q. A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1. Int. J. Nanomedicine, 2012, 7, 4983-4994.
82. Jia, Z.; Lin, P.; Xiang, Y.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. A novel nanomatrix system consisted of colloidal silica and pHsensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur. J. Pharm. Biopharm., 2011, 79(1), 126-134.
83. Kalepu, S., M. Manthina, and V. Padavala, Oral lipid-based drug delivery systems-an overview. Acta. Pharm. Sin. B, 2013, 3(6), 361-372.
84. Griffin, B.T.; O'Driscoll, C.M. Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv., 2011, 2(12), 1633-1653.
85. Prabhu, S.; Ortega, M.; Ma, C. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Int. J. Pharm., 2005, 301(1-2), 209-216.
86. Elden, T.; Speiser, P.; Hincal, A. Optimization of spray-dried and-congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res., 1991, 8(1), 47-54.
87. Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 2007, 59(6), 478-490.
88. Davis, S.S. Coming of age of lipid-based drug delivery systems. Adv. Drug Deliv. Rev., 2004, 56(9), 1241-1242.
89. Battaglia, L.; Trotta, M.; Gallarate, M.; Carlotti, M.E.; Zara, G.P.; Bargoni, A. Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: development and influence on insulin stability. J. Microencapsul., 2007, 24(7), 660-672.
90. Bi, R.; Shao, W.; Wang, Q.; Zhang, N. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J. Biomed. Nanotechnol., 2009, 5(1), 84-92.
91. Fonte, P.; Andrade, F.; Araújo, F.; Andrade, C.; Neves, J.; Sarmento, B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol., 2012, 508, 295-314.
92. Gallarate, M.; Trotta, M.; Battaglia, L.; Chirio, D. Preparation of solid lipid nanoparticles from W/O/W emulsions: Preliminary studies on insulin encapsulation. J. Microencapsul., 2009, 26(5), 394-402.
93. Arrieta-Molero, J.F.; Aleck, K.; Sinha, M.K.; Brownscheidle, C.M.; Shapiro, L.J.; Sperling, M.A. Orally administered liposomeentrapped insulin in diabetic animals. A critical assessment. Horm. Res., 1982, 16(4), 249-256.
94. Dapergolas, G.; Gregoriadis, G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet, 1976, 2(7990), 824-827.
95. Degim, Z.; Unal, N.; Essiz, D.; Abbasoglu, U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci., 2004, 75(23), 2819-2827.
96. Hanato, J.; Kuriyama, K.; Mizumoto, T.; Debari, K.; Hatanaka, J.; Onoue, S.; Yamada, S. Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect. Int. J. Pharm., 2009, 382(1-2), 111-116.
97. Iga, K.; Ogawa, Y.; Toguchi, H. Rates of systemic degradation and reticuloendothelial system (RES) uptake of thermosensitive liposome encapsulating cisplatin in rats. Pharm. Res., 1993, 10(9), 1332-1337.
98. Alving, C.R.; Steck, E.A.; Chapman, W.L. Jr.; Waits, V.B.; Hendricks, L.D.; Swartz, G.M. Jr.; Hanson, W.L. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. USA, 1978, 75(6), 2959-2963.
99. Labuzek, K.; Kozlowski, M.; Szkudlapski, D.; Sikorska, P.; Kozlowska, M.; Okopien, B. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eye? Eur. J. Intern. Med., 2013, 24(3), 207-212.